HYPERGLYCEMIA AND ADVERSE PREGNANCY OUTCOME (HAPO)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a federally funded prospective multi-center trial addressing the effect of hyperglycemia on pregnancy outcome (HAPO). The specific aims are to examine glucose tolerance in a large, heterogeneous, multinational, multi-cultural, ethnically diverse cohort of women in the third trimester of gestation with medical caregivers "blinded" to status of glucose tolerance, and to derive internationally acceptable criteria for the diagnosis and classification of gestational diabetes mellitus that are based on the specific relationships between maternal hyperglycemia and the risk of specific adverse outcomes. Pregnant women will be recruited in early gestation to participate. Those who give informed consent will provide historical and antenatal data and undergo metabolic evaluation (75g OGTT and measurement of hemoglobin A1C at approximately 28 weeks gestation). Cord blood will be collected at delivery for assessment of fetal beta-cell function; neonatal hyperglycemia will be determined at one hour of life; neonatal anthropometrics measured within 24 hours; and data on delivery and neonatal outcomes will be recorded.